Haemophilia: Medical Treatments

Department of Health and Social Care written question – answered on 4th September 2018.

Alert me about debates like this

Photo of Jim Shannon Jim Shannon Shadow DUP Spokesperson (Human Rights), Shadow DUP Spokesperson (Health)

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 June 2018 to Question 154639 on Haemophilia: Medical Treatments, if he will take steps to carry out such a comparative assessment of the uptake of treatment in (a) Ireland, (b) Canada and (c) the EU.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The Department does not routinely make international comparisons on the uptake of individual medicines, and differences in patient demographics, disease burden and clinical practice mean that useful comparison is not always possible. We currently have not plan to undertake an international comparison of haemophilia medicine uptake.

The level of uptake of individual products in England are measured through NHS Digital’s Innovation Scorecard, however this does not include the routine medications for haemophilia.

The Department does publish an indicator for the overall position in competitiveness indicators which can be found in the published Life Sciences Competitiveness Indicators Report at the following link:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/706963/life-sciences-competitiveness-indicators-2018.pdf

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.